NCT04682314|Unknown
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
B-REC
Loading search results
B-REC
Sponsor study identifier
observational
60
0 countries
N/A
Study Start
December 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies. However, patients who have received this treatment have a persistent deficit in humoral immunity up to one year post-transplant. To date, the design of new therapeutic strategies to improve immune recovery in allo-HSCT patients is still hampered by the fact that post-transplant regenerative hematopoiesis has never been studied, and more generally by our currently limited knowledge on the development and function of human B lymphocytes. The main objective of our study is to study early B-cell progenitor reconstitution after allogeneic hematopoietic stem cell transplantation.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 7, 2020
Actual (reported)December 23, 2020
Actual (reported)March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
B cells reconstitution
B cell clusters as assess by CyTOF technology
at day 100 days post-transplant
B cells reconstitution
at 6 months post-transplant
Perturbations in growth or differentiation of progenitor/precursor of B cells
at 100 days post transplant
Perturbations in growth or differentiation of progenitor/precursor of B cells
at 6 months post-transplant
Patients aged 18 years and older with hematological malignancies and subject to allogeneic HSCT
First Submitted
December 7, 2020
First Posted
December 23, 2020
Study Start
December 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 2023
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 23, 2020
Record last verified: 2020-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: